- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01650675
Indirect Assessment and Intervention for Perinatal Drug Use
December 7, 2015 updated by: Steven J. Ondersma, Wayne State University
The purpose of this study is to assess the validity of an indirect computer-delivered screener for drug use and assess the efficacy of a computer-delivered brief intervention with urban post-partum women at-risk for substance abuse and HIV during the post-partum period.
Study Overview
Status
Completed
Conditions
Detailed Description
Two factors limit the potential of brief interventions for the reduction of substance abuse and HIV risk.
First, the ability to conduct such interventions is dependent upon willingness to disclose drug use and risky sexual behaviors.
This is a significant obstacle given evidence that as few as half of drug-positive individuals-particularly women in the perinatal period-report that use.
Second, there are logistic and financial obstacles to implementing even brief intervention programs, particularly with regard to time, training and provider willingness.
In response to these limitations, and with NIDA support (DA018975), the Parent Health Lab at the Wayne State University School of Medicine developed and validated a sensitive indirect screener that evaluates correlates of illicit drug use rather than drug use itself.
The Lab also developed a brief computer-delivered intervention designed to build change motivation without presuming the presence of risks to accompany the screener.
This intervention demonstrated excellent feasibility and acceptability in Phase I testing.
Following NIDA's Stage Model of Behavioral Therapy Development, the proposed study will take the next step of validating the computer-delivered indirect screening and intervention process in a Phase II/Stage IIb trial with women determined to be at risk by the indirect drug use screener.
In addition, given that 47.8% of the prior sample's participants had an STI at some point in their lives, the proposed study will also further expand the existing focus on HIV risk.
Specifically, we plan to: (a) continue development and validation of the WIDUS screener via concomitant collection of WIDUS protocols and hair/urine samples, as well as by building its ability to indirectly predict HIV risk; (b) revise and upgrade the draft indirect intervention based on expert and participant informant feedback; (c) recruit 500 at-risk women from an urban obstetric hospital; and (d) randomly assign participants into intervention and control conditions, with blinded follow-up assessments at 3- and 6-months.
If proven efficacious, this logistically feasible, replicable, and low-cost approach could allow a dramatic increase in the reach--and therefore the population impact--of brief interventions for drug use among at-risk post-partum women.
Further, any impact on maternal drug use would be further multiplied by indirect effects on the at-risk child.
Study Type
Interventional
Enrollment (Actual)
500
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Wayne State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 18 years of age or older
- able to communicate in English
- recently gave birth to healthy infant
Exclusion Criteria:
- received narcotic pain medication in past 3 hours
- no sleep since giving birth
- infant deceased or in intensive care
- psychosis or other clear cognitive impairment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control
Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
|
This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
|
|
Experimental: Indirect intervention
Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area.
This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
|
A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of drug using days
Time Frame: since last research visit; up to 90 days prior to current evaluation
|
Drug use over past 90 days will be measured at a 3 and 6-month follow-up by self-report, hair, and urine analysis.
|
since last research visit; up to 90 days prior to current evaluation
|
|
Change from Baseline HIV and other STI risk at 3 months
Time Frame: since last research visit; up to 90 days from baseline visit
|
Self-report of risky sexual and/or injection drug use that could place participants at risk of HIV and other STIs
|
since last research visit; up to 90 days from baseline visit
|
|
Change from Baseline in HIV and Other STI Risk at 6 months
Time Frame: since last research visit; up to 180 days since baseline visit
|
Self-report of risky sexual and/or injection drug use that could place participants at risk of HIV and other STIs
|
since last research visit; up to 180 days since baseline visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven J Ondersma, Ph.D., Wayne State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
July 13, 2012
First Submitted That Met QC Criteria
July 23, 2012
First Posted (Estimate)
July 26, 2012
Study Record Updates
Last Update Posted (Estimate)
December 8, 2015
Last Update Submitted That Met QC Criteria
December 7, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01DA029050 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Abuse
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Stuart WillickSports Medicine Research and Testing Laboratory; Partnership for Clean CompetitionCompletedSports Drug Abuse | Abuse of Steroids or HormonesUnited States
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
University of Colorado, DenverCompletedMedication AbuseUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
-
Hasselt UniversityZiekenhuis Oost-Limburg; CAD LimburgCompleted
-
INSYS Therapeutics IncCompletedDrug Abuse, MedicationCanada
-
Boston UniversityNational Institute on Drug Abuse (NIDA)WithdrawnIntravenous Drug Abuse
-
University of CopenhagenActive, not recruitingSports Drug AbuseDenmark
Clinical Trials on Nutrition time control/placebo intervention
-
Wayne State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol AbuseUnited States
-
First Affiliated Hospital of Wannan Medical CollegeCompletedTime-restricted Enteral Nutrition Versus Continuous Enteral Nutrition in Patients With Severe StrokeStroke | Time Restricted FeedingChina
-
VA Office of Research and DevelopmentRecruiting
-
The Hong Kong Polytechnic UniversityRecruitingDiabetes | Telemedicine | Self-ControlHong Kong
-
University of HawaiiCompletedGestational Weight GainUnited States
-
Centre Hospitalier le MansCompleted
-
University of MichiganNational Institute of Nursing Research (NINR)CompletedCaregiversUnited States
-
University of MichiganNational Center for Advancing Translational Sciences (NCATS)CompletedCaregiversUnited States
-
VA Office of Research and DevelopmentCompletedMalnutrition | Abdominal Surgery | Nutritional RiskUnited States
-
Universidad de GranadaHospital Clinico Universitario San Cecilio; University Hospital Virgen de las...Recruiting